Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Ibrutinib demonstrated superior response rates and survival for treatment-naïve chronic lymphocytic leukemia (CLL) patients in a pivotal study that excluded patients younger than 65 (
Mato, Anthony R; Roeker, Lindsey E; Allan, John N; Pagel, John M; Brander, Danielle M; Hill, Brian T; Cheson, Bruce D; Furman, Richard R; Lamanna, Nicole; Tam, Constantine S; Handunnetti, Sasanka; Jacobs, Ryan; Lansigan, Frederick; Bhavsar, Erica; Barr, Paul M; Shadman, Mazyar; Skarbnik, Alan P; Goy, Andre; Beach, Douglas F; Svoboda, Jakub; Pu, Jeffrey J; Sehgal, Alison R; Zent, Clive S; Tuncer, Hande H; Schuster, Stephen J; Pickens, Peter V; Shah, Nirav N; Rhodes, Joanna; Ujjani, Chaitra S; and Nabhan, Chadi, "Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial." (2018). Journal Articles and Abstracts. 588.